Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Birtcher/Conmed litigation

This article was originally published in The Gray Sheet

Executive Summary

Birtcher files suit against Conmed, seeking a declaration that the pad monitoring devices used with four of its electrosurgical generators do not infringe a patent held by Conmed subsidiary Aspen Laboratories. The Feb. 24 complaint also seeks to declare Conmed's patent invalid on grounds that the technology is "not new or unique." The filing follows a month of unsuccessful negotiations between the two firms. At the end of the negotiations, Conmed indicated that it intends to charge Birtcher with patent infringement. Conmed says it will issue a response to the Birtcher filing and a countersuit within 30 days. Birtcher has recently prevailed over Beacon and Valleylab in separate patent infringement suits related to argon gas coagulator technology ("The Gray Sheet" Feb. 22, p. 16).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel